Welcome to the Physician Resource Center
Our library of helpful links and patient education resources is designed to provide you with valuable information for use in your practice.
The Minnesota Living with Heart Failure questionnaire is a validated, reliable measure of how HF affects patients' lives using an 0 to 5 QoL scale.
The FDA has determined that BiDil currently has no generic bioequivalent. Moreover, available generics are not indicated to treat HF.
See the full study published in the New England Journal of Medicine.
Resources for patients with heart failure, and caregivers
Explore information and resources designed to help patients and caregivers manage the challenges of heart failure.
Learn about heart failure-related weight gain and the importance of daily weigh-ins.
Learn about heart failure-related fluid retention and the importance of tracking daily fluid intake.
Most salt doesn't come from the salt shaker—Learn how to tell which foods are healthier choices for reducing blood pressure and improving heart health.
Stress doesn't cause long-term conditions like heart failure, but it can have an impact. See how to help manage stress with music, breathing exercises, and more.
Sometimes it's hard to remember all the things you want to cover when you’re at the doctor. This guide will help you have a more productive appointment.
Improving your overall health can help reduce the symptoms of heart failure and may slow the progress of the disease. Here are some healthy living tips that may help.
See Renil's Heart Failure Story
BiDil – the only heart failure medication designed specifically for self-identified African Americans.
Learn about Renil, a 48-year-old nurse with 5 children, who was recently diagnosed with heart failure (HF). Renil’s physician choose BiDil® (isosorbide dinitrate/hydralazine HCl) as part of an overall treatment plan including routine HF medications.
IMPORTANT SAFETY INFORMATION
Most common adverse reactions (>5% more on BiDil than on placebo) were headache and dizziness.Please click here to see full Important Safety Information for BiDil.
Renil’s Heart Failure Story
List of links to organizations and research/clinical trials.
By clicking on a link, you will be leaving the BiDil.com website. We make no representations whatsoever about any other website that you may access through this one.
BiDil has no therapeutic bioequivalent Learn why individual components may not be the answer.
INDICATIONS AND USAGE
BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.
IMPORTANT SAFETY INFORMATION
BiDil is contraindicated in patients who are allergic to organic nitrates, or who take phosphodiesterase type 5 (PDE5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulator (riociguat). Concomitant use can cause hypotension.
WARNINGS AND PRECAUTIONS
Hydralazine hydrochloride has been reported to cause a drug-induced systemic lupus erythematosus (SLE) syndrome. Symptoms and signs usually regress when hydralazine hydrochloride is discontinued.
Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil. Hypotension is most likely to occur in patients who have been volume or salt depleted; correct prior to initiation of BiDil. Hydralazine hydrochloride can cause tachycardia and hypotension potentially leading to myocardial ischemia and angina, particularly in patients with hypertrophic cardiomyopathy.
Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect. Pyridoxine should be added to BiDil therapy if such symptoms develop.
Most common adverse reactions (> 5% more on BiDil than on placebo) were headache and dizziness.